Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn

Clinical TrialsFDATherapuetics
Written By Corey Hubbard
Pfizer's Sickle Cell Strategy Stumbles Inclacumab Fails Phase III
Glassbury Team

GlassBury Cares Podcast

Episode #32

Corey Hubbard
Previous

Unlock the Alzheimer's Enigma: Science, Struggle, and the Art of Connection
Next

Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule